QNCXHealthcare · BiotechnologyThe 8 Wall Street analysts covering Quince Therapeutics, Inc. hold a median 12-month price target of $70 — +161.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 6 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Quince Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (86): Smaller than most of the companies we track.
Momentum (3): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on QNCX, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
The green dot is the last close — the median target sits +161.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 24 Sept 2026 | Rodman & Renshaw | Initiates | Buy | $70 |
| 22 Sept 2026 | Citizens | Upgrade | Market Outperform | $77 |
| 18 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | $70 |
| 18 Aug 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 29 July 2026 | Oppenheimer | Initiates | Outperform | — |
| 29 July 2026 | Oppenheimer | Initiates | Outperform | $82 |
| 24 June 2026 | Leerink Partners | Initiates | Outperform | $4.00 |
| 24 June 2026 | Leerink Partners | Initiates | Outperform | — |
| 23 June 2026 | Cantor Fitzgerald | Initiates | Overweight | $4.00 |
| 23 June 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 30 Jan 2026 | Citizens | Downgrade | Market Perform | — |
| 30 Jan 2026 | D. Boral Capital | Downgrade | Hold | — |
| 29 Jan 2026 | D. Boral Capital | Maintains | Buy | — |
| 15 Dec 2025 | D. Boral Capital | Maintains | Buy | — |
| 13 Nov 2025 | D. Boral Capital | Maintains | Buy | — |
| 26 Sept 2025 | D. Boral Capital | Maintains | Buy | — |
| 15 Aug 2025 | D. Boral Capital | Maintains | Buy | — |
| 12 Aug 2025 | JMP Securities | Maintains | Market Outperform | — |
| 5 Aug 2025 | JMP Securities | Initiates | Market Outperform | — |
| 17 July 2025 | D. Boral Capital | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QNCX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 77% of US stocks
Cheaper than 97% of US stocks
Cheaper than 67% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 13% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Quince Therapeutics, Inc. has a market value of $28.6M and an enterprise value of $56.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$92.5M.
Free cash flow in the twelve months to 30 June 2026: −$47.0M.
Trailing P/E: −0.1×; forward P/E: −6.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Quince Therapeutics, Inc. employs 38 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Quince Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of Quince Therapeutics, Inc.’s shareholder/analyst call prepared remarks.
Why it matters — The transcript provides QNCX watchers with the company’s prepared remarks from a shareholder/analyst call.
Quince Therapeutics, Inc. discussed the clinical progress of its LAM-001 program in a Seeking Alpha transcript covering developments in pulmonary hypertension and bronchiolitis obliterans syndrome. The item presents the company's update on LAM-001's clinical advancement in these indications.
Why it matters — A QNCX watcher would care because this transcript provides insight into the clinical progress of LAM-001, one of the company's key pipeline programs.
Quince Therapeutics announced it will host a virtual key opinion leader event on September 28, 2026, to discuss the current treatment landscape for PH-ILD and BOS and the potential role of LAM-001 as a therapeutic option. The event was announced on September 17, 2026.
Why it matters — The event offers QNCX watchers an opportunity to learn how LAM-001 could fit into the treatment landscape for the serious, underserved conditions PH-ILD and BOS.
Quince Therapeutics announced that senior management will participate in investor conferences scheduled for September 2026. The company, a clinical stage biopharmaceutical firm focused on disease-modifying therapies for underserved conditions, will present at these events.
Why it matters — Investor conference participation gives QNCX watchers an opportunity to hear directly from senior management about the company's clinical-stage pipeline and strategy.
Quince Therapeutics reported its second quarter 2026 financial results and issued a corporate update. The company completed its acquisition of Orphai Therapeutics, which added LAM-001, an inhaled formulation of rapamycin for treating multiple serious, underserved pulmonary diseases, to its pipeline.
Why it matters — QNCX watchers would care because the completed Orphai acquisition expands the company's pipeline with a new inhaled therapeutic candidate targeting serious pulmonary diseases.
The 8 Wall Street analysts covering Quince Therapeutics, Inc. have a median 12-month price target of $70, with estimates ranging from $65 to $98. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Quince Therapeutics, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Quince Therapeutics, Inc. 31 out of 100 across roughly 4,600 US stocks as at 6 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 6 Oct 2026, Quince Therapeutics, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +161.1% from the last close, and Ticker Nerd's factor model ranks Quince Therapeutics, Inc. 31 out of 100 as at 6 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Quince Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QNCX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $65 to $98 over the next 12 months.
Quince Therapeutics Inc. is a biotechnology company focused on developing and commercializing therapies for serious rare diseases.
The most recent item we track (Seeking Alpha, 6 Oct 2026): "Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript". Seeking Alpha published a transcript of Quince Therapeutics, Inc.’s shareholder/analyst call prepared remarks.
Quince Therapeutics Inc. is a biotechnology company focused on developing and commercializing therapies for serious rare diseases. The company’s current work centers on its proprietary Autologous Intracellular Drug Encapsulation platform, designed to deliver treatments using a patient’s own red blood cells. Its lead development programs target rare pediatric neurodegenerative and pulmonary conditions, reflecting a focus on underserved areas with limited treatment options. Quince Therapeutics serves the specialty biopharmaceutical market by advancing disease-modifying therapies intended for patients with debilitating disorders, while also building capabilities in drug-device combination technologies and clinical-stage development.
CEO Dr. Dirk Thye M.D. · 38 employees · United States · https://quincetx.com